The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Antiretroviral and anti-hepatitis C virus direct-acting antiviral-related hepatotoxicity
Han H, Agarwal R, Martel-Laferriere V, Dieterich DT. Clin Liver Dis. 2013 Nov;17(4):657-70, ix. doi: 10.1016/j.cld.2013.07.007. Epub 2013 Sep 4.
Source
Department of Medicine, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue, Annenberg 21-42, New York, NY 10029, USA.
Abstract
Antiretroviral-related hepatotoxicity occurs commonly in patients with human immunodeficiency virus (HIV). Liver injury ranges from unconjugated hyperbilirubinemia and nodular regenerative hyperplasia to lactic acidosis and toxic hepatitis. Effective antiretroviral therapy has changed coinfected patients' primary morbidities and mortality to chronic liver disease rather than complications from HIV. Treatment for hepatitis C virus (HCV) is strongly encouraged early in all coinfected patients. However, drug-drug interactions must be considered to ensure safe and tolerable use alone or in combination with antiretroviral therapies. The first-generation and newer HCV direct-acting antivirals are promising in coinfected patients, with minimal side effects and hepatotoxicity.